Sax Wealth Advisors LLC Buys 86 Shares of Eli Lilly and Company $LLY

Sax Wealth Advisors LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 14.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 689 shares of the company’s stock after acquiring an additional 86 shares during the quarter. Sax Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $537,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LLY. PNC Financial Services Group Inc. increased its stake in shares of Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after buying an additional 50,002,551 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after buying an additional 4,975,395 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Eli Lilly and Company by 0.6% in the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock valued at $10,495,261,000 after buying an additional 81,587 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Eli Lilly and Company by 13.3% in the first quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock valued at $4,808,443,000 after buying an additional 682,203 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in shares of Eli Lilly and Company in the first quarter valued at $4,613,912,000. 82.53% of the stock is owned by institutional investors.

Insider Transactions at Eli Lilly and Company

In other news, CEO David A. Ricks bought 1,632 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jamere Jackson bought 200 shares of the business’s stock in a transaction on Friday, August 8th. The stock was purchased at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. This represents a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Leerink Partnrs lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. JPMorgan Chase & Co. lowered their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, September 16th. DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday. Finally, Guggenheim lifted their price objective on Eli Lilly and Company from $875.00 to $948.00 and gave the stock a “buy” rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $943.00.

Eli Lilly and Company Trading Up 0.2%

NYSE LLY opened at $845.55 on Thursday. The stock has a market capitalization of $800.28 billion, a price-to-earnings ratio of 55.26, a PEG ratio of 1.18 and a beta of 0.47. The stock’s 50 day moving average price is $738.69 and its two-hundred day moving average price is $766.57. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.